Is Voyager Therapeutics Poised to Win Big With Parkinson's Treatment?

Health and Healthcare

Published: June 21, 2018 9:15 am

Last Updated: January 11, 2020 10:05 pm

For many drug developers, Parkinson’s disease is a tricky disease to treat. However, developing a treatment ultimately could yield a huge reward as there are currently no therapies that effectively slow or reverse the progression of this disease. And after Thursday’s announcement, Voyager Therapeutics Inc. (NASDAQ: VYGR) could be poised to reap this reward.

Voyager shares made a solid gain early on Thursday after the company announced a key U.S. Food and Drug Administration (FDA) approval related to its Parkinson’s treatment. Specifically, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for Voyager’s VY-AADC gene therapy treatment for Parkinson’s disease in patients with motor fluctuations that are refractory to medical management.

Recently established under the 21st Century Cures Act, RMAT designation is an expedited program for the advancement and approval of regenerative medicine products, including gene therapy products. The designation includes all the benefits of the FDA’s Fast Track and Breakthrough Therapy designation programs.

Robert Pietrusko, Pharm.D., senior vice president of regulatory affairs and quality assurance at Voyager, commented:

The RMAT designation was based on our Phase 1b clinical data with VY-AADC and represents an important milestone for the program and recognition of this gene therapy as a potential treatment for Parkinson’s disease. We look forward to working closely with the agency through the benefits of the RMAT designation for guidance on the development of VY-AADC including advice to generate evidence needed to support its potential approval in an efficient manner.

Shares of Voyager closed Wednesday at $21.17, with a consensus analyst price target of $31.55 and a 52-week range of $8.10 to $31.91. Following the announcement, the stock was up about 15% at $24.24 in early trading indications Thursday.

24/7 Wall St.
18 American Companies That Control What You Buy

The Average American Has No Idea How Much Money You Can Make Today ^(Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

¹https://www.fdic.gov/national-rates-and-rate-caps